Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Simultaneous Treatment with Statins and Aspirin Reduces the Risk of Prostate Cancer Detection and Tumorigenic Properties in Prostate Cancer Cell Lines

  • Olivan, Mireia|||0000-0002-8464-0827
  • Rigau, M.
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • Garcia, M..
  • Montes, Melania|||0000-0002-4268-6608
  • Sequeiros, T.
  • Regis, Lucas|||0000-0001-7121-1946
  • Celma, Ana|||0000-0002-3128-3811
  • Planas, J.
  • Placer, José
  • Reventós, J.
  • de Torres, Inés|||0000-0002-5495-9140
  • Doll, Andreas|||0000-0001-8965-8682
  • Morote Robles, Juan|||0000-0002-2168-323X
Nowadays prostate cancer is the most common solid tumor in men from industrialized countries and the second leading cause of death. At the ages when PCa is usually diagnosed, mortality related to cardiovascular morbidity is high; therefore, men at risk for PCa frequently receive chronic lipid-lowering and antiplatelet treatment. The aim of this study was to analyze how chronic treatment with statins, aspirin, and their combination influenced the risk of PCa detection. The tumorigenic properties of these treatments were evaluated by proliferation, colony formation, invasion, and migration assays using different PCa cell lines, in order to assess how these treatments act at molecular level. The results showed that a combination of statins and aspirin enhances the effect of individual treatments and seems to reduce the risk of PCa detection (OR: 0.616 (95% CI: 0.467-0.812), P < 0.001). However, if treatments are maintained, aspirin (OR: 1.835 (95% CI: 1.068-3.155), P = 0.028) or the combination of both drugs (OR: 3.059 (95% CI: 1.894-4.939), P < 0.001) represents an increased risk of HGPCa. As observed at clinical level, these beneficial effects in vitro are enhanced when both treatments are administered simultaneously, suggesting that chronic, concomitant treatment with statins and aspirin has a protective effect on PCa incidence.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer

  • Sequeiros, Tamara|||0000-0002-0908-2263
  • Rigau, Marina|||0000-0002-1691-454X
  • Chiva, Cristina
  • Montes, Melania|||0000-0002-4268-6608
  • Garcia-Grau, Iolanda
  • García, Marta|||0000-0001-5155-4730
  • Diaz-Mercedes, Sherley|||0000-0002-8164-8639
  • Celma, Ana|||0000-0002-3128-3811
  • Bijnsdorp, Irene
  • Campos, Alexandre
  • Di Mauro, Primiano
  • Borrós, Salvador|||0000-0002-4003-0381
  • Reventós, Jaume
  • Doll, Andreas|||0000-0001-8965-8682
  • Paciucci, Rosanna|||0000-0001-5651-5933
  • Pegtel, Michiel
  • de Torres, Inés|||0000-0002-5495-9140
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Olivan, Mireia|||0000-0002-8464-0827
Rapid and reliable diagnosis of prostate cancer (PCa) is highly desirable as current used methods lack specificity. In addition, identification of PCa biomarkers that can classify patients into high- and low-risk groups for disease progression at early stage will improve treatment decision-making. Here, we describe a set of protein-combination panels in urinary extracellular vesicles (EVs), defined by targeted proteomics and immunoblotting techniques that improve early non-invasive detection and stratification of PCa patients.We report a two-protein combination in urinary EVs that classifies benign and PCa patients (ADSV-TGM4), and a combination of five proteins able to significantly distinguish between high- and low-grade PCa patients (CD63-GLPK5-SPHM-PSA-PAPP). Proteins composing the panels were validated by immunohistochemistry assays in tissue microarrays (TMAs) confirming a strong link between the urinary EVs proteome and alterations in PCa tissues. Moreover, ADSV and TGM4 abundance yielded a high diagnostic potential in tissue and promising TGM4 prognostic power. These results suggest that the proteins identified in urinary EVs distinguishing high- and low grade PCa are a reflection of histological changes that may be a consequence of their functional involvement in PCa development. In conclusion, our study resulted in the identification of protein-combination panels present in urinary EVs that exhibit high sensitivity and specificity for PCa detection and patient stratification. Moreover, our study highlights the potential of targeted proteomic approaches-such as selected reaction monitoring (SRM)-as diagnostic assay for liquid biopsies via urinary EVs to improve diagnosis and prognosis of suspected PCa patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples

  • Olivan, Mireia|||0000-0002-8464-0827
  • García, Marta
  • Suárez, Leticia|||0000-0002-3864-4616
  • Guiu, Marc|||0000-0002-7083-986X
  • Gros, Laura
  • Méndez Fernández, Olga
  • Rigau, Marina|||0000-0002-1691-454X
  • Reventós, Jaume
  • Segura, Miguel F.|||0000-0003-0916-3618
  • de Torres, Inés|||0000-0002-5495-9140
  • Planas, Jacques|||0000-0002-0222-584X
  • de la Cruz, Xavier|||0000-0002-9738-8472
  • Gomis, Roger R..|||0000-0001-6473-2858
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Rodríguez-Barrueco, Ruth|||0000-0003-4925-8865
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
Prostate cancer (PCa) is the most prevalent cancer in males worldwide, and it was the fifth leading cause of cancer mortality in this group in 2020. Near 70% of advanced-stage PCa patients will undergo bone metastasis, suffering pathological complications that severely affect patients' quality of life and probably progress in most cases to lethal PCa. Our main objective was to unveil novel molecules associated with choosing the bone as a metastatic niche. For this purpose, we generated and characterized a cell line with increased tropism to bone. Its molecular analysis has led us to identify factors with a potential role in bone metastasis that could also be used as biomarkers of disease progression. These data help us to understand the mechanisms that increase bone metastasis penetrance of PCa cells and could provide new therapeutic tools in the future for patients with worse prognoses. About 70% of advanced-stage prostate cancer (PCa) patients will experience bone metastasis, which severely affects patients' quality of life and progresses to lethal PCa in most cases. Hence, understanding the molecular heterogeneity of PCa cell populations and the signaling pathways associated with bone tropism is crucial. For this purpose, we generated an animal model with high penetrance to metastasize to bone using an intracardiac percutaneous injection of PC3 cells to identify PCa metastasis-promoting factors. Using genomic high-throughput analysis we identified a miRNA signature involved in bone metastasis that also presents potential as a biomarker of PCa progression in human samples. In particular, the downregulation of miR-135b favored the incidence of bone metastases by significantly increasing PCa cells' migratory capacity. Moreover, the PLAG1, JAKMIP2, PDGFA, and VTI1b target genes were identified as potential mediators of miR-135b's role in the dissemination to bone. In this study, we provide a genomic signature involved in PCa bone growth, contributing to a better understanding of the mechanisms responsible for this process. In the future, our results could ultimately translate into promising new therapeutic targets for the treatment of lethal PCa.